Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt